An Open Prospective Randomized Clinical Study of the Effectiveness, Tolerability and Safety of a Single Intraperitoneal Use of the Drug "Prospidelong, Powder for the Preparation of a Gel for Topical Use, 1000 mg in Vials, Package No. 1" in Patients With Disseminated Gastric Cancer, Phase I-II

It is planned to conduct an open-label, prospective, randomized clinical study of the efficacy, tolerability and safety of a single intraperitoneal administration of the investigational drug Prospidelong at a dose of 4000 mg (2000 mg in terms of prospidium chloride) in patients with disseminated gastric cancer.
In total, the study plans to include 120 patients aged 18 to 75 years inclusive, including 60 patients in the study group and 60 in the comparison group. The study consists of daily examination of patients throughout the entire period of hospitalization and subsequent visits.

Start Date01 Jun 2024

Sponsor / Collaborator

Unitary Enterprise UNITEHPROM BSU

100 Clinical Results associated with Prospidium chloride

100 Translational Medicine associated with Prospidium chloride

100 Patents (Medical) associated with Prospidium chloride

Literatures (Medical) associated with Prospidium chloride

01 Jan 2001·Bulletin of Experimental Biology and MedicineQ4 · MEDICINE

New experimental model of multiple myeloma.

Q4 · MEDICINE

Article

Author: A. R. Kalinina ; A. A. Ovsepyan ; G. B. Telegin ; N. A. Ponomarenko ; S. G. Homeriki ; V. V. Tsybenko ; S. V. Smirnov

NSO/1 (P3x63Ay 8Ut) and SP20 myeloma cells were inoculated to BALB/c OlaHsd mice. NSO/1 cells allowed adequate stage-by-stage monitoring of tumor development. The adequacy of this model was confirmed in experiments with conventional cytostatics: prospidium and cytarabine caused necrosis of tumor cells and reduced animal mortality.

01 Jan 1984·Revista espanola de oncologia

[Treatment with intratumoral prospidium chloride of cancer of the mammae induced by N-nitrosomethylurea in the rat].

Article

Author: Urcia, M ; Pérez-López, F R ; Guillén, V ; Hergueta, J ; Leal, M C ; Lafarga, L

Wistar rats bearing N-nitrosomethylurea-induced mammary tumors received intratumoral injections of prospidium chloride or saline. Each tumor with 30-100 mm2 (the product of the two largest perpendicular diameters) received 20 mg of prospidium chloride diluted in 100 microliter of saline, and increasing amounts of 20 mg of the product in the same volume for every additional 100 mm2 or fraction of tumor. After a week the treatment was repeated in the same way. Control rats received only saline without prospidium chloride. No significant differences were observed regarding the tumor area, total tumor area/rat, and body weight when comparing the rats receiving prospidium chloride and the control rats. Prospidium chloride does not show any direct oncolytic effect upon the experimental model employed.

01 Jan 1984·Voprosy onkologii

[In vitro sensitivity of epidermoid lung cancer to cytostatics depending upon the degree of tumor differentiation].

Article

Author: Murnietse, E V ; Plegere, D A ; Berzin'sh, Iu A ; Zitare, I Ia ; Grants, E A

In vitro sensitivity of epidermoid lung carcinoma to chemotherapeutic agents in short-term cultures versus degree of tumor differentiation was evaluated for the following drugs: 5-fluorouracil, methotrexate, olivomycin, bleomycin, carminomycin, adriablastin, prospidium chloride, vincristine, thiophosphamide, novembichine and photrine. The results of the investigation using resected material from 77 cases of histologically confirmed epidermoid lung carcinoma failed to establish any relationship between the parameters under study for all above drugs except vincristine. However, tumors showing similar levels of differentiation demonstrated different sensitivity to certain drugs.

100 Deals associated with Prospidium chloride

External Link

KEGG	Wiki	ATC	Drug Bank
-	Prospidium chloride	-	-

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Stomach Cancer	Phase 3	BY	Unitary Enterprise UNITEHPROM BSU	01 Jun 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


EULAR2003	Not Applicable	Rheumatoid Arthritis	110	Prospidin + Methotrexate	glrswnjnwi(qdrnosbdcp) = fybbbuscvw ekmoqhmyfk (jlmsupcvpf ) View more	-	18 Jun 2003
				Methotrexate	glrswnjnwi(qdrnosbdcp) = kxibqijxqy ekmoqhmyfk (jlmsupcvpf ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Prospidium chloride

Overview

Basic Info

Structure

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation